Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Cash from Operations (2022 - 2025)

Historic Cash from Operations for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to -$3.7 million.

  • TriSalus Life Sciences' Cash from Operations rose 6580.62% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.2 million, marking a year-over-year increase of 5207.95%. This contributed to the annual value of -$40.8 million for FY2024, which is 1924.75% up from last year.
  • TriSalus Life Sciences' Cash from Operations amounted to -$3.7 million in Q3 2025, which was up 6580.62% from -$7.3 million recorded in Q2 2025.
  • In the past 5 years, TriSalus Life Sciences' Cash from Operations ranged from a high of -$425954.0 in Q1 2022 and a low of -$22.9 million during Q3 2022
  • Over the past 4 years, TriSalus Life Sciences' median Cash from Operations value was -$9.2 million (recorded in 2023), while the average stood at -$9.3 million.
  • In the last 5 years, TriSalus Life Sciences' Cash from Operations plummeted by 236575.92% in 2023 and then soared by 6580.62% in 2025.
  • TriSalus Life Sciences' Cash from Operations (Quarter) stood at -$8.3 million in 2022, then fell by 10.43% to -$9.2 million in 2023, then surged by 37.81% to -$5.7 million in 2024, then skyrocketed by 35.01% to -$3.7 million in 2025.
  • Its Cash from Operations was -$3.7 million in Q3 2025, compared to -$7.3 million in Q2 2025 and -$4.5 million in Q1 2025.